Toxicity and survival associated with IV/IP chemotherapy following neoadjuvant chemotherapy and interval debulking surgery for epithelial ovarian, fallopian tube, and primary peritoneal cancer

被引：0
|
作者：
Rios-Doria, E. [1 ]
Pezzillo, M. [1 ]
Ulm, M. A. [2 ]
Tillmanns, T. [2 ]
机构：
[1] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA
[2] Univ Tennessee, West Canc Ctr, Memphis, TN USA
来源：
GYNECOLOGIC ONCOLOGY | 2020年 / 159卷
关键词：
D O I：
10.1016/j.ygyno.2020.05.157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
269
引用
收藏
页码：127 / 128
页数：2
相关论文
共 50 条
  • [21] PROGRESSION FREE SURVIVAL COMPARISON WITH NEOADJUVANT CHEMOTHERAPY AND PRIMARY DEBULKING SURGERY IN ADVANCED EPITHELIAL OVARIAN CANCER
    Lee, Y. J.
    Kim, Y. M.
    Lee, S. H.
    Park, J. Y.
    Suh, D. S.
    Kim, D. Y.
    Kim, J. H.
    Kim, Y. T.
    Nam, J. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1416 - 1416
  • [22] Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.
    Liu, Ying L.
    Zhou, Qin
    Iasonos, Alexia
    Filippova, Olga T.
    Chi, Dennis
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger J.
    Broach, Vance
    O'Cearbhaill, Roisin Eilish
    Konner, Jason A.
    Aghajanian, Carol
    Long-Roche, Kara C.
    Tew, William P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer - a retrospective cohort study
    Maricic, Slobodan
    Mandic, Aljosa
    Dejanovic, Ninoslav
    Kladar, Nebojsa
    Popovic, Marina
    Ivkovic-Kapicl, Tatjana
    Gutic, Bojana
    Kokanov, Dunja
    VOJNOSANITETSKI PREGLED, 2021, 78 (11) : 1193 - 1199
  • [24] NEOADJUVANT CHEMOTHERAPY AND INTERVAL DEBULKING FOR ADVANCED EPITHELIAL OVARIAN-CANCER
    JACOB, JH
    GERSHENSON, DM
    MORRIS, M
    COPELAND, LJ
    BURKE, TW
    WHARTON, JT
    GYNECOLOGIC ONCOLOGY, 1991, 42 (02) : 146 - 150
  • [25] Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer
    Nishio, Shin
    Ushijima, Kimio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (04) : 379 - 386
  • [26] Survival and toxicity of a modified GOG 172 IP chemotherapy regimen in patients with ovarian, fallopian tube or primary peritoneal carcinoma
    Becker, D.
    Haygood, C. L. Walters
    Smith, B.
    Bevis, K. S.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 176 - 177
  • [27] Primary debulking surgery versus neoadjuvant chemotherapy in elderly patients with epithelial ovarian cancer
    Xu, Z.
    Justiniano, C. F.
    Fleming, F. J.
    Boscoe, F. P.
    Schymura, M. J.
    Rubinsak, L. A.
    Morrow, G.
    Minasian, L.
    Temkin, S. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 78 - 78
  • [28] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    Alexandre A. B. A. da Costa
    Camila V. Valadares
    Glauco Baiocchi
    Henrique Mantoan
    Augusto Saito
    Solange Sanches
    Andréia P. Guimarães
    Maria Isabel W. Achatz
    Annals of Surgical Oncology, 2015, 22 : 971 - 978
  • [29] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    da Costa, Alexandre A. B. A.
    Valadares, Camila V.
    Baiocchi, Glauco
    Mantoan, Henrique
    Saito, Augusto
    Sanches, Solange
    Guimaraes, Andreia P.
    Achatz, Maria Isabel W.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S971 - S978
  • [30] Benefits of neoadjuvant chemotherapy in ovarian, primary peritoneal, or fallopian tube carcinoma.
    Brown, Alaina J.
    Huang, Marilyn
    Sun, Charlotte C.
    Zaid, Tarrik M.
    Balakrishnan, Nyla
    Mhadgut, Hemendra
    Lu, Karen H.
    Westin, Shannon Neville
    Bodurka, Diane C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345